Discovering and developing transformative therapies for challenging disorders of the brain and nervous system
A spin-out of Naurex Pharmaceuticals, Aptinyx is discovering and developing innovative treatments for neurological disorders where there is a significant unmet need for improved therapies. The company is building a platform of novel compounds that precisely modulate the N-methyl-D-aspartate (NMDA) receptor, which plays a pivotal role in brain and nervous system function and disorders. Aptinyx is led by several members of the Naurex team, who successfully led the sale of Naurex to Allergan for a total consideration of up to $1.71B in 2015.
